The heat shock response, heat shock genes and proteins, heat shock transcription factor HSF1 and cancer

The stress or heat shock response (HSR) is a key mechanism for maintaining cellular proteostasis under conditions of heat or other proteotoxic stress. The response encompasses increased expression of so-called heat shock proteins (HSPs), molecular chaperones that reduce aggregation of misfolded proteins and promote their refolding or disposal (1,2). Activation of the HSR is triggered by protein damage that occurs in cells exposed to excessive but non-lethal heat or to chemicals or other conditions that cause proteins to become denatured (3,4).

The master regulator of the mammalian HSR is heat shock transcription factor 1 (HSF1) (5,6). In the absence of a stress, HSF1 is predominantly present in cells in an inactive, hetero-oligomeric complex comprising HSP90 and co-chaperones (7-10). Several additional proteins are known or inferred to bind HSF1 or HSF1 complex, including CHIP (11), HDAC6 (12,13), p97/VCP (12,13), DAXX (14), 14-3-3 (15), FILIP-1L (16) and HSBP1 (17). More recently, this list was expanded considerably by Fujimoto et al. and, most notably, now includes ATF1 and RPA1, which proteins interact with the HSF1 DNA-binding domain (18,19).

Stress-mediated activation of HSF1 and maintenance of the factor in an active form involves a multitude of events. An early event is the dissociation of HSP90 or HSP90 complex from the inactive HSF1 complex and the consequential homo-trimerization of HSF1 (7,20). HSF1 trimers are capable of specifically binding to so-called heat shock elements (HSE) present in promoters of target genes. However, whether the latter HSF1 trimers are also transactivation-competent appears to depend in part on whether they are capable of escaping re-association with HSP90 and/or HSP70 (21,22). Transcriptional activity of HSF1 will also depend on DAXX as well as on its phosphorylation status (14, 23-25). Recruitment of HSF1 to target promoters in response to a stress is mediated by ATF1/CREB (19). ATF1/CREB regulates the stress-induced HSF1 transcription complex that includes BRG1 chromatin-remodeling complex and p300/CBP. The former complex promotes an active chromatin state in the promoters, whereas p300/CBP accelerates the shutdown of HSF1 DNA-binding activity as well as stabilizes HSF1 against proteasomal degradation during recovery from stress (19,26). This shutdown is counteracted by SIRT1-mediated deacetylation (27).

Beyond the regulation of typical HSR genes such as HSP genes, activated HSF1 influences the activities of genes related to a variety of basic cellular processes. This HSF1-induced program may facilitate oncogenic transformation and maintenance of a malignant phenotype (28-33). Dai and colleagues demonstrated that genetic elimination of HSF1 protects mice from tumors induced by mutations in the RAS oncogene or a hot spot mutation in tumor suppressor gene P53 and that ablation of HSF1 by RNA interference is cytotoxic to various cancer cell lines (31). Work by others in different in vitro and in vivo cancer models permitted the generalization of these findings (34-37). Consistent with the dependence of many cancers on HSF1 activity is the observation of elevated nuclear levels of HSF1 in a high proportion of breast cancer samples from in situ and invasive breast carcinomas obtained from 1841 participants (38). High levels of HSF1 were correlated with poor survival. A subsequent study found high levels of nuclear HSF1 to be common in a wide range of cancers (30). These findings propound HSF1 as a promising new cancer therapeutic target.

Adapted from Vilaboa et al (2017) Nucleic Acids Res 45: 5797-817.


1. Richter K, Haslbeck M, Buchner J (2010) Mol Cell 40: 253-266

2. Hartl FU, Bracher A, Hayer-Hartl M (2011) Nature 475: 324-332

3. Ananthan J, Goldberg AL, Voellmy R (1986) Science 232: 522-524

4. Hightower LE (1980) J Cell Physiol 102: 407-427

5. McMillan DR, Xiao X, Shao L, Graves K, Benjamin IJ (1998) J Biol Chem 273: 7523-7528

6. Akerfelt M, Morimoto RI, Sistonen L (2010) Nat Rev Mol Cell Biol 11: 545-555

7. Zou J, Guo Y, Guettouche T, Smith DO, Voellmy R (1998) Cell 94: 471-480

8. Ali A, Bharadwaj S, O’Carroll R, Ovsenek N (1998) Mol Cell Biol 18: 4949-4960

9. Duina AA, Kalton HM, Gaber RF (1998) J Biol Chem 273: 18974-18978

10. Voellmy R, Boellmann F (2007) Adv Exp Med Biol 594: 89-99

11. Dai Q, Zhang C, Wu Y, McDonough H, Whaley RA, Godfrey V, Li HH, Madamanchi N, Xu W, Neckers L et al (2003) EMBO J 22 : 5446-5458

12. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, Garrido C, Yao T-P, Vourc’h C, Matthias P et al (2007) Genes Dev 21: 2172-2181

13. Pernet L, Faure V, Gilquin B, Dufour-Guérin S, Khochbin S, Vourc’h C (2014) Mol Biol Cell 25: 4187-4194

14. Boellmann F, Guettouche T, Guo Y, Fenna M, Mnayer L, Voellmy R (2004) Proc Natl Acad Sci USA 101: 4100-4105

15. Wang XZ, Grammatikakis N, Siganou A, Stevenson MA, Calderwood SK (2004). J Biol Chem 279: 49460-49469

16. Hu Y, Mivechi NF (2011) J Biol Chem 286: 31397-31408

17. Satyal SH, Chen D, Fox SG, Kramer JM, Morimoto RI (1998) Genes Dev 12: 1962-1974

18. Fujimoto M, Takaki E, Takii R, Tan K, Prakasam R, Hayashida N, Iemura S-I, Natsume T, Nakai A (2012) Mol Cell 48: 182-194

19. Takii R, Fujimoto M, Tan K, Takaki E, Hayashida N, Nakato R, Shirahige K, Nakai A (2015) Mol Cell Biol 35: 11-25

20. Rabindran SK, Haroun RI, Clos J, Wisniewski J, Wu C (1993) Science 259: 230-234

21. Guo Y, Guettouche T, Fenna M, Boellmann F, Pratt WB, Toft DO, Smith DF, Voellmy,R. (2001) J Biol Chem 276: 45791-45799

22. Shi Y, Mosser DD, Morimoto RI (1998) Genes Dev 12: 654-666

23. Guettouche T, Boellmann F, Lane WS, Voellmy R (2005) BMC Biochemistry 6: 4

24. Chou S-D, Prince T, Gong J,  Calderwood SK (2012) PLoS ONE 7: e39679

25. Hietakangas V, Ahlskog JK, Jakobsson AM, Hellesuo M, Sahlberg NM, Holmberg CI, Mikhailov A, Palvimo JJ, Pirkkala L, Sistonen L (2003) Mol Cell Biol 23: 2953-2968

26. Raychaudhuri S, Loew C, Körner R, Pinkert S, Theis M, Hayer-Hartl M, Buchholz F, Hartl FU (2014) Cell 156: 975-985

27. Westerheide SD, Anckar J, Stevens Jr SM, Sistonen L, Morimoto RI (2009) Science 323: 1063-1066

28. Trinklein ND, Murray JI, Hartman SJ, Botstein D, Myers RM (2004) Mol Biol Cell 15: 1254-1261

29. Page TJ, Sikder D, Yang L, Pluta L, Wolfinger RD, Kodadek T, Thomas RS (2006) Mol Biosyst 2: 627-639

30. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L, Lindquist S (2012) Cell 150: 549-562

31. Dai C, Whitesell L, Rogers AB, Lindquist S (2007) Cell 130: 1005-1018

32. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M (2009) Oncogene 28: 3689-3701

33. Ciocca DR, Arrigo AP, Calderwood SK (2013) Arch Toxicol 87: 19-48

34. Khaleque MA, Bharti A, Sawyer D, Gong J, Benjamin IJ, Stevenson MA, Calderwood SK (2005) Oncogene 24: 6564-6573

35. Nakamura Y, Fujimoto M, Hayashida N, Takii R, Nakai A, Muto M (2010) J Derm Sci 60: 187-192

36. Meng L, Gabai VL, Sherman MY (2010) Oncogene 29: 5204-5213

37. Gabai VL, Meng L, Kim G, Mills TA, Benjamin IJ, Sherman MY (2012) Mol Cell Biol 32: 929-940

38. Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinso SE, Schnitt SJ, Whitesell L, Tamimi RM, Lindquist S et al (2011) Proc Natl Acad Sci USA 108: 18378-18383

Comments are closed.